{
  "id": 16246330,
  "title": "Windward Bio files for Nasdaq IPO to fund China-derived assets and in-house R&D",
  "url": "https://urgent.news/2026/10/23/windward-bio-files-for-nasdaq-ipo-to-fund-china-derived-assets-and-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-23T23:15:09.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/windward-bio-files-for-nasdaq-ipo-to-fund-china-derived-assets-and-in-house-rd/"
  },
  "original_language": "en",
  "account": null,
  "summary": "A 2-year-old European biotech with two clinical-stage assets from China is the latest to attempt an initial public offering in the US. Basel-based Windward Bio submitted its cards for a Nasdaq ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Windward Bio seeks Nasdaq listing to fund respiratory, skin disease drug trials",
        "url": "https://urgent.news/2026/10/24/windward-bio-seeks-nasdaq-listing-to-fund-respiratory-skin-disease",
        "published": "2026-10-24T00:08:40.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}